[
  {
    "ts": null,
    "headline": "Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma",
    "summary": "WILMINGTON, Del., October 19, 2025--Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced CRC and KRAS G12D Inhibitor in Advanced PDAC",
    "url": "https://finnhub.io/api/news?id=0ad1ce5a8ad40b5e50ce9c6b340548fe8eb6fd75bbf3c06488f86942ae61b411",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760895000,
      "headline": "Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma",
      "id": 137165687,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "WILMINGTON, Del., October 19, 2025--Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced CRC and KRAS G12D Inhibitor in Advanced PDAC",
      "url": "https://finnhub.io/api/news?id=0ad1ce5a8ad40b5e50ce9c6b340548fe8eb6fd75bbf3c06488f86942ae61b411"
    }
  }
]